JP7143295B2 - ピペリジン－２，６－ジオン誘導体及びクローン病の治療 - Google Patents
ピペリジン－２，６－ジオン誘導体及びクローン病の治療 Download PDFInfo
- Publication number
- JP7143295B2 JP7143295B2 JP2019528110A JP2019528110A JP7143295B2 JP 7143295 B2 JP7143295 B2 JP 7143295B2 JP 2019528110 A JP2019528110 A JP 2019528110A JP 2019528110 A JP2019528110 A JP 2019528110A JP 7143295 B2 JP7143295 B2 JP 7143295B2
- Authority
- JP
- Japan
- Prior art keywords
- dione
- pharmaceutically acceptable
- acceptable salts
- isoindoline
- dioxopiperidin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611041317.5 | 2016-11-24 | ||
| CN201611041317 | 2016-11-24 | ||
| PCT/CN2017/112669 WO2018095378A1 (zh) | 2016-11-24 | 2017-11-23 | 哌啶-2,6-二酮衍生物以及克罗恩氏病的治疗 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020500204A JP2020500204A (ja) | 2020-01-09 |
| JP2020500204A5 JP2020500204A5 (enExample) | 2020-08-20 |
| JP7143295B2 true JP7143295B2 (ja) | 2022-09-28 |
Family
ID=62194806
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019528110A Active JP7143295B2 (ja) | 2016-11-24 | 2017-11-23 | ピペリジン－２，６－ジオン誘導体及びクローン病の治療 |
| JP2019528114A Active JP7143296B2 (ja) | 2016-11-24 | 2017-11-23 | ピペリジン－２，６－ジオン誘導体及び潰瘍性結腸炎の治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019528114A Active JP7143296B2 (ja) | 2016-11-24 | 2017-11-23 | ピペリジン－２，６－ジオン誘導体及び潰瘍性結腸炎の治療 |
Country Status (7)
| Country | Link |
|---|---|
| US (4) | US20220372013A2 (enExample) |
| EP (2) | EP3546450A4 (enExample) |
| JP (2) | JP7143295B2 (enExample) |
| CN (2) | CN108101886A (enExample) |
| AU (2) | AU2017366514B2 (enExample) |
| CA (2) | CA3049161C (enExample) |
| WO (2) | WO2018095378A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7143295B2 (ja) | 2016-11-24 | 2022-09-28 | ティアンジン ヘメイ ファーマスーティカル サイ－テック カンパニー リミテッド | ピペリジン－２，６－ジオン誘導体及びクローン病の治療 |
| CN108727319A (zh) * | 2018-09-05 | 2018-11-02 | 常州大学 | 一种3-硝基邻苯二甲酸酐的制备方法 |
| CN109293631B (zh) * | 2018-11-30 | 2020-05-08 | 常州制药厂有限公司 | 3-氨基-n-(2，6-二氧代-3-哌啶基)-邻苯二甲酰亚胺化合物的制备方法 |
| GB202002926D0 (en) * | 2020-02-28 | 2020-04-15 | Benevolentai Tech Limited | Compositions and uses thereof |
| CN111320604B (zh) * | 2020-04-22 | 2021-02-09 | 牡丹江医学院 | 一种治疗小儿口腔黏膜疾病的化合物、制备方法及其用途 |
| CN118370746A (zh) * | 2024-04-25 | 2024-07-23 | 江苏省中医院 | 马尿酸在制备溃疡性结肠炎治疗药物中的应用 |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002070480A1 (es) | 2001-03-01 | 2002-09-12 | Fundacion Universitaria San Pablo Ceu | Derivados de glutarimida como agentes terapeuticos |
| CN1961876A (zh) | 2005-11-08 | 2007-05-16 | 北京恩华医药研究院 | 邻苯二甲酰亚胺衍生物在制备抗新血管生成的药物中的用途 |
| JP2008534631A (ja) | 2005-04-07 | 2008-08-28 | 天津和美生物技▲術▼有限公司 | 細胞の腫瘍壊死因子釈放を抑制できるピペリジン−２，６−−ジオン誘導物 |
| JP4703554B2 (ja) | 2003-03-27 | 2011-06-15 | 天津和美生物技術有限公司 | 水溶性のサリドマイド誘導体 |
| JP2013535009A (ja) | 2010-06-18 | 2013-09-09 | 大鵬薬品工業株式会社 | Ｐｒｐｋ−ｔｐｒｋｂモジュレーター及びその使用 |
| JP2020500205A (ja) | 2016-11-24 | 2020-01-09 | 天津和美生物技術有限公司 | ピペリジン−２，６−ジオン誘導体及び潰瘍性結腸炎の治療 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1336602A1 (en) * | 2002-02-13 | 2003-08-20 | Giovanni Scaramuzzino | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases |
| SG133603A1 (en) * | 2003-09-17 | 2007-07-30 | Us Gov Health & Human Serv | Thalidomide analogs as tnf-alpha modulators |
| KR20070099031A (ko) | 2005-01-25 | 2007-10-08 | 셀진 코포레이션 | 4-아미노-2-(3-메틸-2,6-디옥소피페리딘-3-일)-이소인돌-1,3-디온을 사용한 방법 및 조성물 |
| US9839632B2 (en) | 2013-04-02 | 2017-12-12 | Celgene Corporation | Methods and compositions using 4-amino-2-(2,6-dioxo-piperidine-3-yl)-isoindoline-1,3-dione for treatment and management of central nervous system cancers |
-
2017
- 2017-11-23 JP JP2019528110A patent/JP7143295B2/ja active Active
- 2017-11-23 JP JP2019528114A patent/JP7143296B2/ja active Active
- 2017-11-23 CN CN201711184758.5A patent/CN108101886A/zh active Pending
- 2017-11-23 CN CN201711185728.6A patent/CN108101887A/zh active Pending
- 2017-11-23 CA CA3049161A patent/CA3049161C/en active Active
- 2017-11-23 EP EP17874499.1A patent/EP3546450A4/en active Pending
- 2017-11-23 AU AU2017366514A patent/AU2017366514B2/en active Active
- 2017-11-23 WO PCT/CN2017/112669 patent/WO2018095378A1/zh not_active Ceased
- 2017-11-23 EP EP17873820.9A patent/EP3546449A4/en active Pending
- 2017-11-23 CA CA3045703A patent/CA3045703C/en active Active
- 2017-11-23 AU AU2017366515A patent/AU2017366515B2/en active Active
- 2017-11-23 US US16/464,228 patent/US20220372013A2/en active Pending
- 2017-11-23 WO PCT/CN2017/112668 patent/WO2018095377A1/zh not_active Ceased
- 2017-11-23 US US16/464,224 patent/US11485724B2/en active Active
-
2022
- 2022-06-03 US US17/832,518 patent/US11873287B2/en active Active
-
2023
- 2023-12-08 US US18/533,755 patent/US12331030B2/en active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002070480A1 (es) | 2001-03-01 | 2002-09-12 | Fundacion Universitaria San Pablo Ceu | Derivados de glutarimida como agentes terapeuticos |
| JP4703554B2 (ja) | 2003-03-27 | 2011-06-15 | 天津和美生物技術有限公司 | 水溶性のサリドマイド誘導体 |
| JP2008534631A (ja) | 2005-04-07 | 2008-08-28 | 天津和美生物技▲術▼有限公司 | 細胞の腫瘍壊死因子釈放を抑制できるピペリジン−２，６−−ジオン誘導物 |
| CN1961876A (zh) | 2005-11-08 | 2007-05-16 | 北京恩华医药研究院 | 邻苯二甲酰亚胺衍生物在制备抗新血管生成的药物中的用途 |
| JP2013535009A (ja) | 2010-06-18 | 2013-09-09 | 大鵬薬品工業株式会社 | Ｐｒｐｋ−ｔｐｒｋｂモジュレーター及びその使用 |
| JP2020500205A (ja) | 2016-11-24 | 2020-01-09 | 天津和美生物技術有限公司 | ピペリジン−２，６−ジオン誘導体及び潰瘍性結腸炎の治療 |
Non-Patent Citations (1)
| Title |
|---|
| International Journal of Nanomedicine，2011年，No.6，pp.2007-2021 |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017366515A1 (en) | 2019-06-13 |
| WO2018095378A1 (zh) | 2018-05-31 |
| CN108101887A (zh) | 2018-06-01 |
| US20240132466A1 (en) | 2024-04-25 |
| US20190352277A1 (en) | 2019-11-21 |
| US20190389835A1 (en) | 2019-12-26 |
| US11873287B2 (en) | 2024-01-16 |
| CA3049161A1 (en) | 2018-05-31 |
| AU2017366514A1 (en) | 2019-06-13 |
| CA3049161C (en) | 2023-03-07 |
| CN108101886A (zh) | 2018-06-01 |
| JP2020500205A (ja) | 2020-01-09 |
| WO2018095377A1 (zh) | 2018-05-31 |
| AU2017366514B2 (en) | 2021-01-21 |
| EP3546450A4 (en) | 2020-06-10 |
| JP7143296B2 (ja) | 2022-09-28 |
| EP3546449A1 (en) | 2019-10-02 |
| US20220306600A1 (en) | 2022-09-29 |
| US20220372013A2 (en) | 2022-11-24 |
| CA3045703A1 (en) | 2018-05-31 |
| JP2020500204A (ja) | 2020-01-09 |
| AU2017366515B2 (en) | 2021-01-21 |
| US12331030B2 (en) | 2025-06-17 |
| EP3546450A1 (en) | 2019-10-02 |
| EP3546449A4 (en) | 2020-06-10 |
| CA3045703C (en) | 2021-11-02 |
| US11485724B2 (en) | 2022-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7143295B2 (ja) | ピペリジン－２，６－ジオン誘導体及びクローン病の治療 | |
| CN115515944A (zh) | 苯并噻唑类衍生物及其用途 | |
| JPWO2004014428A1 (ja) | 腸疾患および内臓痛の治療薬 | |
| CN112638866A (zh) | 索拉非尼衍生物的共晶体及其制备方法 | |
| JPS62145049A (ja) | アミノスチリル化合物及びそれを有効成分とするロイコトリエンきつ抗剤 | |
| US11767295B2 (en) | Isoindole derivative | |
| US9907792B2 (en) | Acetic acid ester compound or salt thereof | |
| US11639332B2 (en) | Methods and compositions of isoindoline-1,3-dione and isoindole prodrugs useful for treating cancer, ulcerative colitis and related inflammatory diseases | |
| CN106946851B (zh) | 一种用于预防和治疗肾结石的药物 | |
| HK40050156A (en) | Co-crystal of sorafenib derivatives and process for preparation thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200709 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200709 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20200721 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20210520 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210525 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20210825 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211004 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20211005 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20211221 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20220318 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220520 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20220823 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20220914 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7143295 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |